<table>
<thead>
<tr>
<th><strong>STEP ONE: SELECT CLINICAL SCENARIO</strong></th>
<th><strong>STEP TWO: GATHER CLINICAL OUTCOMES</strong></th>
<th><strong>STEP THREE: GATHER ADDITIONAL DATA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADDITION (Row I)</strong>  OR REPLACEMENT (Row II)</td>
<td><strong>ADDITION of Targeted Therapy to Standard</strong> For example, Trastuzumab added to chemotherapy for HER2+ breast cancer.</td>
<td><strong>COSTS</strong>  - Obtain cost data from Medicare reimbursement amounts (ie RED BOOK pricing).  - Scale data to unit cost/yr  - Select range for sensitivity analysis based on  - If data does not exist for emerging therapy, please use surrogate data from similar pharmaceutical class.</td>
</tr>
<tr>
<td><strong>REPLACEMENT</strong></td>
<td><strong>REPLACEMENT of Standard with Targeted Therapy</strong> For example, first-line Crizotinib therapy in NSCLC with ALK rearrangement</td>
<td><strong>HRQOL</strong>  - Ideally, HRQOL data will be reported as secondary outcome in randomized trials.  - Alternatively, HRQOL data can be gathered from literature search for meta-analysis for specific cancer type (e.g. [25])  - Alternatively, HRQOL data can be estimated from published compendiums (e.g. [27])</td>
</tr>
</tbody>
</table>

**Median Biomarker Prevalence:** ____  
95% CI: [ ____ to ____ ]

**Median PFS ____**  
95% CI: [ ____ to ____ ]

**Median OS ____**  
95% CI: [ ____ to ____ ]

**Cost of Test:** ____; Range: [ ____ to ____ ]

**Cost of Targeted Therapy:** ____;  
Range: [ ____ to ____ ]

**Cost of Standard Therapy:** ____

**Cost of Progressed Disease:** ____

**Determine cost/year from literature search of existing cost analysis, ensuring tumor staging/characteristics consistency with clinical trial data.**

- **HRQOL of Targeted Therapy:** ____;  
  Range: [ ____ to ____ ]
- **HRQOL of Standard Therapy:** ____
- **HRQOL of Progressed Disease:** ____

**Duration of Std. Treatment ____ ; 95% CI: [ ____ to ____ ]**

**Cost of Test:** ____; Range: [ ____ to ____ ]  
- **Cost of Targeted Therapy:** ____;  
  Range: [ ____ to ____ ]  
- **Cost of Standard Therapy:** ____

**Cost of Progressed Disease:** ____

**Determine cost/year from literature search of existing cost analysis, ensuring tumor staging/characteristics consistency with clinical trial data.**

- **HRQOL of Progressed Disease:** ____
- **HRQOL of Stable Disease:** ____

- **Overall survival data unavailable, please disregard outlined variables. Note that this calculation will then assume ΔOS = ΔPFS.**

- **If OS is unavailable, please disregard outlined variables. Note that the calculation will then assume ΔOS = ΔPFS.**